UNITED THERAPEUTICS Corp (UTHR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US91307C1027
UNITED THERAPEUTICS Corp financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.18 bn USD |
| Gross profit | 2.80 bn USD |
| Operating income | 1.49 bn USD |
| EBIT | 1.54 bn USD |
| Net income | 1.33 bn USD |
| Diluted EPS – continuing operations | 27.86 USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About UNITED THERAPEUTICS Corp
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
More stocks
- ENTEGRIS INC (ENTG)
- Sungrow Power Supply Co Ltd (300274.SZ)
- Mediobanca Banca di Credito Finanziario SpA (MB.MI)
- Capgemini SE (CAP.PA)
- Next PLC (NXT.L)
- Principal Financial Group (PFG)
- VAT Group AG (VACN.SW)
- ROKU, INC (ROKU)
- International Flavors & Fragrances (IFF)
- Tapestry, Inc. (TPR)
- Genmab A/S (GMAB.CO)
- SGS SA (SGSN.SW)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.